These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 3960398
1. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum. Fuxe K, Meller E, Goldstein M, Benfenati F, Agnati LF. Neurosci Lett; 1986 Feb 28; 64(2):163-8. PubMed ID: 3960398 [Abstract] [Full Text] [Related]
5. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone. Lazareno S, Nahorski SR. Eur J Pharmacol; 1982 Jul 09; 81(2):273-85. PubMed ID: 7117377 [Abstract] [Full Text] [Related]
6. 125I-Spiperone: a novel ligand for D2 dopamine receptors. Gundlach AL, Largent BL, Snyder SH. Life Sci; 1984 Nov 05; 35(19):1981-8. PubMed ID: 6149442 [Abstract] [Full Text] [Related]
13. In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors. Bischoff S, Bittiger H, Krauss J. Eur J Pharmacol; 1980 Dec 05; 68(3):305-15. PubMed ID: 7202494 [Abstract] [Full Text] [Related]
14. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation. Chivers JK, Reavill C, Jenner P, Marsden CD. J Pharm Pharmacol; 1988 Sep 05; 40(9):613-9. PubMed ID: 2907027 [Abstract] [Full Text] [Related]
15. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists. Giorgi O, Biggio G. Brain Res; 1990 Nov 12; 533(1):53-9. PubMed ID: 1982234 [Abstract] [Full Text] [Related]
16. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands. Urwyler S, Coward D. Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb 12; 335(2):115-22. PubMed ID: 2951601 [Abstract] [Full Text] [Related]
17. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum. Zahniser NR, Dubocovich ML. J Pharmacol Exp Ther; 1983 Dec 12; 227(3):592-9. PubMed ID: 6655559 [Abstract] [Full Text] [Related]
18. Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Farabegoli C, Merlo Pich E, Cimino M, Agnati LF, Fuxe K. Acta Physiol Scand; 1988 Feb 12; 132(2):209-16. PubMed ID: 2906500 [Abstract] [Full Text] [Related]
19. Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats. Ekman A, Eriksson E. Life Sci; 1991 Feb 12; 48(4):321-31. PubMed ID: 1824955 [Abstract] [Full Text] [Related]
20. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. Nowak G, Arnt J, Hyttel J. Eur J Pharmacol; 1988 Aug 24; 153(2-3):309-11. PubMed ID: 3053212 [Abstract] [Full Text] [Related] Page: [Next] [New Search]